A study developed pH- and enzyme-responsive micelles for PD-1 and PTX codelivery, resulting in synergistic cancer chemoimmunotherapy via antitumor immunity by PTX-induced immunogenic cell death (ICD), while aPD-1 blocks the PD-1/PD-L1 axis to suppress immune escape due to PTX-induced PD-L1 upregulation [109]. Here, CD274 is linked to cancer.